FDA Acquiring ‘Fresh’ Aborted Baby Parts to Make Mice With Human Immune Systems

By Terrence P. Jeffrey
CNS News

The U.S. Food and Drug Administration signed a new contract on July 25 to acquire “fresh” human fetal tissue to transplant into “humanized mice” so that these mice will have a functioning “human immune system,” according to information published by the FDA and the General Services Administration.

“The objective is to acquire Tissue for Humanized Mice,” said a June 13 FDA “presolicitation notice” for the contract.

The contractor, the notice said, would “provide the human fetal tissue needed to continue the ongoing research being led by FDA.

“Fresh human tissues are required,” said the notice, “for implantation into severely immune-compromised mice to create chimeric animals that have a human immune system.”

According to GSA’s federal contract database, Advanced Bioscience Resources (ABR), a non-profit organization based in the San Francisco Bay Area, was awarded this $15,900 contract, which will run through July 25, 2019.

“Fetal tissue used in research is obtained from elective abortions,” says the Congressional Research Service.

In 2016, Harvard University provided the House Energy and Commerce Committee’s Select Investigative Panel on Infant Lives with a background paper explaining that mice with human immune systems “are engineered to this condition only by means of the use of human fetal material” and that this material can only come from aborted babies not from miscarriages. (See the Harvard backgrounder by clicking here.)

Thus, by issuing a contract to acquire human fetal tissue to use in making mice with human immune systems, the FDA is using federal tax dollars to create a demand for human body parts that must be taken from babies who are aborted.

Because it would not be able to create its “humanized mice” without fresh tissue taken from aborted babies, the FDA also has an interest in the continuation of legalized abortions at a stage in fetal development when the tissue needed to create these mice can be retrieved from the aborted baby.


The above graphic depicting the creation of a humanized mouse was included in a November 2016 FDA presentation posted on the FDA's website.

While the FDA confirmed to CNSNews.com that its June 13 presolicitation notice for a contract to “acquire Tissue for Humanized Mice” and the July 25 contract it signed with ABR (as reported on the GSA contract database) refer to the same deal, the FDA declined to answer 17 other questions CNSNews.com asked it about that contract and the aborted baby parts it requires the contractor to provide. (See the full set of questions CNSNews.com sent to the FDA by clicking here.)

CNS News article continues here